Stock CELU CELULARITY INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Celularity Inc.

Equities

CELU

US1511902041

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
3.11 USD +4.36% Intraday chart for Celularity Inc. -10.12% +25.71%
May. 21 Transcript : Celularity Inc. - Analyst/Investor Day
Mar. 26 Celularity Receives Healthcare Common Procedure Coding System Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Harnessing natural killer cells to combat age-related diseases
AQ
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
AQ
Transcript : Celularity Inc. - Analyst/Investor Day
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy
AQ
Celularity Inc. to Host Investor and Analyst Research and Development Day
AQ
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
AQ
Celularity Inc. to Host Investor and Analyst Research & Development Day
AQ
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
AQ
Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024
AQ
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024, Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products
AQ
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products
AQ
Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells
AQ
Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L
AQ
Celularity Receives Healthcare Common Procedure Coding System Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L
CI
Celularity Seeks FDA Orphan Drug Status for PDA-002 in Facioscapulohumeral Muscular Dystrophy
MT
Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
AQ
Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit
AQ
Celularity Inc. announced that it expects to receive $10 million in funding from Yorkville Advisors Global LP
CI
Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress
AQ
Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CELU Stock
  4. News Celularity Inc.